A Study of LY3337641 in Japanese and Caucasian Healthy Participants
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 20 - 64 |
| Updated: | 6/23/2017 |
| Start Date: | March 15, 2017 |
| End Date: | September 2017 |
A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3337641 in Japanese and Caucasian Healthy Subjects
The main purpose of this study is to evaluate the safety and tolerability of LY3337641 in
healthy Japanese and Caucasian participants. The study will also investigate how the body
processes LY3337641 and the effect of LY3337641 on the body. The study will last up to 4
weeks for each participant. Screening may occur within 28 days prior to first dose of study
drug.
healthy Japanese and Caucasian participants. The study will also investigate how the body
processes LY3337641 and the effect of LY3337641 on the body. The study will last up to 4
weeks for each participant. Screening may occur within 28 days prior to first dose of study
drug.
Inclusion Criteria:
- Overtly healthy Japanese or Caucasian
- Body mass index (BMI) 18.0 - 32.0 kilograms per square meter (kg/m²)
Exclusion Criteria:
- Are currently enrolled in a clinical trial involving an investigational product or
off-label use of a drug or device or are concurrently enrolled in any other type of
medical research judged not to be scientifically or medically compatible with this
study
- Have participated, within the last 30 days, in a clinical trial involving an
investigational product. If the previous investigational product has a long
half-life, 3 months or 5 half-lives (whichever is longer, if known) should have
passed
- Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of
the investigator, increases the risks associated with participating in the study or
affects or confounds the QTc analysis or have Fridericia-corrected QT interval (QTcF)
>450 milliseconds (msec) for males and >470 msec for females
- Have had symptomatic herpes zoster within 3 months of screening
- Have active or latent tuberculosis (TB) based on a positive medical history,
examination, and/or TB test results.
- Have received live vaccine(s) within 1 month of screening or intend to during the
study
- Are immunocompromised
- Have a history of constipation or have had acute constipation within 3 weeks prior to
admission
We found this trial at
1
site
Click here to add this to my saved trials
